Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Lehman who wrote (791)	1/21/1998 9:20:00 PM
From: Harold Engstrom	Respond to of 1501

HL, I confess that I don't know. I saw the pretty graph and was duly impressed - probably more the docile sheep than the animal being testing on VLA4. I think the response being measured was inflammation - so I choose physiological as the category. But, again, I think a call to Biogen is probably in order. The theme at Biogen's annual meeting was their products aimed at inflammation and VLA4 was at center stage. But, I don't know much specifically about the development path for VLA4 nor anything about Inflazyme's apparently competitive product - for all I know Inflazyme may have a superior product.